Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4 Trial)

Recruiting in Palo Alto (17 mi)

+54 other locations

Overseen ByRonald Petersen, MD, PHD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of Southern California

No Placebo Group

Trial Summary

What is the purpose of this trial?Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.

Eligibility Criteria

Participant Groups

3Treatment groups

Experimental Treatment

Group I: Mild Cognitive Impairment (MCI)Experimental Treatment6 Interventions

450 participants with mild cognitive impairment (MCI), which is anticipated to include 250 newly enrolled participants and 200 rollover participants from the prior ADNI3 study with MCI.

Group II: Dementia (DEM)Experimental Treatment6 Interventions

350 participants with mild dementia (DEM), which is anticipated to include 250 newly enrolled participants and 100 participants followed from the prior ADNI3 study with dementia.

Group III: Cognitively Normal (CN)Experimental Treatment6 Interventions

700 participants with no apparent memory problems, which is anticipated to include 250 newly enrolled participants and 450 rollover participants from the prior ADNI3 study without apparent memory problems.